Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers
1997

Methylation Status of the BRCA2 Promoter in Breast and Ovarian Cancers

Sample size: 82 publication Evidence: moderate

Author Information

Author(s): N Collins, R Wooster, MR Stratton

Primary Institution: Institute of Cancer Research

Hypothesis

Is the expression of the BRCA2 gene suppressed in sporadic breast cancers by increased methylation of cytosine residues in the promoter region?

Conclusion

Methylation was not detected in any of the tissues examined, suggesting that this mechanism of transcriptional repression is unlikely to explain the absence of somatic mutations in sporadic cancers.

Supporting Evidence

  • Methylation was not detected in peripheral blood leucocytes from sporadic breast cancer cases.
  • Similar studies showed allele loss on chromosome 13q in 30% of cases.
  • Somatic mutations in BRCA2 are very rare in sporadic cancers.

Takeaway

The study looked at whether a gene related to breast cancer, BRCA2, is turned off by a process called methylation. They found that this process doesn't happen in the cancers they studied.

Methodology

The presence of 5-methylcytosine in three CpG dinucleotides within the BRCA2 promoter was assessed using a digestion-polymerase chain reaction based assay.

Limitations

The study only examined three CpG dinucleotides, which may not fully represent the methylation status of the entire BRCA2 CpG island.

Participant Demographics

Included 64 primary sporadic breast cancers and 18 breast or ovarian cancer cell lines.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication